In the European Union, the fully human lgG4 anti-PD-1 antibody nivolumab is an established option for the treatment of patients with locally advanced or metastatic, squamous non-small cell lung cancer (NSCLC) who have experienced progression on or after chemotherapy. The efficacy of this treatment was shown in the open-label, randomized, phase III CheckMate 017 study, which yielded superior overall survival (OS) outcomes with nivolumab over docetaxel (median OS, 9.2 vs. 6.0 months; HR, 0.59; p = 0.00025) [1].
展开▼
机译：在欧盟，完全人IgG4抗PD-1抗体nivolumab是用于治疗在化疗中或化疗后进展的局部晚期或转移性鳞状非小细胞肺癌（NSCLC）患者的既定选择。该治疗的疗效在开放标签，随机，III期CheckMate 017研究中得到证明，该研究在使用nivolumab的情况下比多西他赛产生了更好的总体生存（OS）结果（中位OS，9.2 vs. 6.0个月; HR，0.59; p = 0.00025）[1]。
展开▼
